Characterization of empty capsids from a conditionally replicating adenovirus for gene therapy

Human Gene Therapy

Volumn 16, Issue 1, 2005, Pages 109-125

  Sutjipto, Suganto ^a   Ravindran, Sundari ^a   Cornell, Douglas ^a   Liu, Yan Hui ^a   Horn, Mark ^a   Schluep, Thomas ^a   Hutchins, Beth ^a   Vellekamp, Gary ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DISULFIDE; HEXON ASSOCIATED PROTEIN VI; HEXON ASSOCIATED PROTEIN VIII; OLIGOMER; PROTEIN L1 52 55K; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; COLUMN CHROMATOGRAPHY; DENSITY GRADIENT CENTRIFUGATION; ELECTRON MICROSCOPY; GENE THERAPY; HUMAN; HUMAN CELL; INFECTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; VIRUS CAPSID; VIRUS REPLICATION;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; CAPSID; CELL LINE; CELL SEPARATION; CENTRIFUGATION, DENSITY GRADIENT; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; MASS SPECTROMETRY; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 13844292515     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.109     Document Type: Article

References (43)

1. BLANCHE, F., MONEGIER, B., FAUCHER, D., DUCHESNE, M., AUDHUY, F., BARBOT, A., BOUVIER, S., DAUDE, G., DUBOIS, H., GUILLEMIN, T., and MATON, L. (2001). Polypeptide composition of an adenovirus type 5 used in cancer gene therapy. J. Chromatogr. A 921, 39-48.
2. BRUNER, R., and VINOGRAD, J. (1965). The evaluation of standard sedimentation coefficients of sodium RNA and sodium DNA from sedimentation velocity data in concentrated NaCl and CsCl solutions. Biochim. Biophys. Acta 108, 18-29.
3. BURLINGHAM, B.T., BROWN, D.T., and DOERFLER, W. (1974). Incomplete particles of adenovirus. 1. Characteristics of the DNA associated with incomplete adenovirions of types 2 and 12. Virology 60, 419-430.
4. CARAVOKYRI, C., and LEPPARD, K.N. (1995). Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J. Virol. 69, 6627-6633.
5. CHELIUS, D., HUHMER, A.F., SHIEH, C.H., LEHMBERG, E., TRAINA, J.A., SLATTERY, T.K., and PUNGOR, E., Jr. (2002). Analysis of the adenovirus type 5 proteome by liquid chromatography and tandem mass spectrometry methods. J. Proteome Res. 1, 501-513.
6. COLBY, W.W., and SHENK, T. (1981). Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J. Virol. 39, 977-980.
7. D'HALLUIN, J.C., MARTIN, G.R., TORPIER, G., and BOULANGER, P.A. (1978). Adenovirus type 2 assembly analyzed by reversible cross-linking of labile intermediates. J. Virol. 26, 357-363.
8. DULBECCO, R., and VOGT, M. (1954). Plaque formation and isolation of pure lines with poliomyelitis viruses. J. Exp. Med. 99, 167-182.
9. EDVARDSSON, B., EVERITT, E., JORNVALL, H., PRAGE, L., and PHILIPSON, L. (1976). Intermediates in adenovirus assembly. J. Virol. 19, 533-547.
10. GUSTIN, K.E., and IMPERIALE, M.J. (1998). Encapsidation of viral DNA requires the adenovirus L1 52/55-kilodalton protein. J. Virol. 72, 7860-7870.
11. GUSTIN, K.E., LUTZ, P., and IMPERIALE, M.J. (1996). Interaction of the adenovirus L1 52/55-kilodalton protein with the IVa2 gene product during infection. J. Virol. 70, 6463-6467.
12. HASSON, T.B., ORNELLES, D.A., and SHENK, T. (1992). Adenovirus L1 52- and 55-kilodalton proteins are present within assembling virions and colocalize with nuclear structures distinct from replication centers. J. Virol. 66, 6133-6142.
13. HUYGHE, B.G., LIU, X., SUTJIPTO, S., SUGARMAN, B.J., HORN, M.T., SHEPARD, H.M., SCANDELLA, C.J., and SHABRAM, P. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403-1416.
14. KAY, M.A., GLORIOSO, J.C., and NALDINI, L. (2001). Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40.
15. LEHMBERG, E., TRAINA, J.A., CHAKEL, J.A., CHANG, R.J., PARKMAN, M., MCCAMAN, M.T., MURAKAMI, P.K., LAHIDJI, V., NELSON, J.W., HANCOCK, W.S., NESTAAS, E., and PUNGOR, E., Jr. (1999). Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. J. Chromatogr. B Biomed. Sci. Appl. 732, 411-423.
16. LEHMBERG, E., SHABRAM, P., SCHLUEP, T., WEN, S.F., SUGARMAN, B., CROYLE, M., KOEHL, M., BONFILS, E., MALARME, D., SHARPE, G., NESBIT, H., BORELLINI, F., KAMEN, A., HUTCHINS, B., and VELLEKAMP, G. (2003). Adenovirus Reference Material: Determination of particle concentrations obtained by orthogonal, physical-chemical methods. Bioprocess. J. 2, 50-55.
17. r proteins. J. Virol. 57, 839-847.
18. MAIZEL, J.V., Jr., WHITE, D.O., and SCHARFF, M.D. (1968a). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115-125.
19. MAIZEL, J.V., Jr., WHITE, D.O., and SCHARFF, M.D. (1968b). The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 36, 126-136.
20. MANGEL, W.F., MCGRATH, W.J., TOLEDO, D.L., and ANDERSON, C.W. (1993). Viral DNA and a viral peptide can act as cofactors of adenovirus virion proteinase activity. Nature 361, 274-275.
21. MANGEL, W.F., TOLEDO, D.L., BROWN, M.T., MARTIN, J.H., and MCGRATH, W.J. (1996). Characterization of three components of human adenovirus proteinase activity in vitro. J. Biol. Chem. 271, 536-543.
22. MATTHEWS, D.A., and RUSSELL, W.C. (1994). Adenovirus protein-protein interactions: Hexon and protein VI. J. Gen. Virol. 75, 3365-3374.
23. MORIN, N., and BOULANGER, P. (1984). Morphogenesis of human adenovirus type 2: Sequence of entry of proteins into previral and viral particles. Virology 136, 153-167.
24. MURAKAMI, P., and MCCAMAN, M.T. (1999). Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal. Biochem. 274, 283-288.
25. PERKINS, D.N., PAPPIN, D.J., CREASY, D.M., and COTTRELL, J.S. (1999). Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567.
26. PRAGE, L., HOGLUND, S., and PHILIPSON, L. (1972). Structural proteins of adenoviruses. 8. Characterization of incomplete particles of adenovirus type 3. Virology 49, 745-757.
27. RAMACHANDRA, M., RAHMAN, A., ZOU, A., VAILLANCOURT, M., HOWE, J.A., ANTELMAN, D., SUGARMAN, B., DEMERS, G.W., ENGLER, H., JOHNSON, D., and SHABRAM, P. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol. 19, 1035-1041.
28. RANCOURT, C., KEYVANI-AMINEH, H., SIRCAR, S., LABRECQUE, P., and WEBER, J.M. (1995). Proline 137 is critical for adenovirus protease encapsidation and activation but not enzyme activity. Virology 209, 167-173.
29. ROITSCH, C., ACHSTETTER, T., BENCHAIBI, M., BONFILS, E., CAUET, G., GLOECKLER, R., L'H, TE, H., KEPPI, E., NGUYEN, M., SPEHNER, D., VAN, DORSSELAER, A., and MALARME, D. (2001). Characterization and quality control of recombinant adenovirus vectors for gene therapy. J. Chromatogr. B Biomed. Sci. Appl. 752, 263-280.
30. ROVOZZO, G.C., and BURKE, C.N. (1973). A Manual of Basic Virological Techniques. (Prentice-Hall, Englewood Cliffs, NJ) pp. 126-133.
31. SCHIEDNER, G., CLEMENS, P.R., VOLPERS, C., and KOCHANEK, S. (2002). High-capacity "gutless" adenoviral vectors: Technical aspects and applications. In Adenoviral Vectors for Gene Therapy. D.T. Curiel and J.T. Douglas, eds. (Academic Press, London) pp. 429-446.
32. SHABRAM, P.W., GIROUX, D.D., GOUDREAU, A.M., GREGORY, R.J., HORN, M.T., HUYGHE, B.G., LIU, X., NUNNALLY, M.H., SUGARMAN, B.J., and SUTJIPTO, S. (1997). Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8, 453-465.
33. SHEVCHENKO, A., WILM, M., VORM, O., and MANN, M. (1996). Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858.
34. STEWART, P.L., FULLER, S.D., and BURNETT, R.M. (1993). Difference imaging of adenovirus: Bridging the resolution gap between x-ray crystallography and electron microscopy. EMBO J. 12, 2589-2599.
35. TIBBETTS, C., and GIAM, C.Z. (1979). In vitro association of empty adenovirus capsids with double-stranded DNA. J. Virol. 32, 995-1005.
36. TOTH, M., TARODI, B., and BELADI, I. (1982). Preparative separation of intact incomplete and empty adenovirus type 2 particles. Acta Virol. 26, 217-220.
37. VELLEKAMP, G., PORTER, F.W., SUTJIPTO, S., CUTLER, C., BONDOC, L., LIU, Y.H., WYLIE, D., CANNON-CARLSON, S., TANG, J.T., FREI, A., VOLOCH, M., and ZHUANG, S. (2001). Empty capsids in column-purified recombinant adenovirus preparations. Hum. Gene Ther. 12, 1923-1936.
38. VELLEKAMP, G., RAVINDRAN, S., LIN, M., SLUZKY, V., and LEHMBERG, E. (2002). A contaminant in the Adenovirus Reference Material. Bioprocessing 1, 56-61.
39. WEBSTER, A., RUSSELL, S., TALBOT, P., RUSSELL, W.C., and KEMP, G.D. (1989). Characterization of the adenovirus proteinase: Substrate specificity. J. Gen. Virol. 70, 3225-3234.
40. WEBSTER, A., HAY, R.T., and KEMP, G. (1993). The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell 72, 97-104.
41. WINBERG, G., and WADELL, G. (1977). Structural polypeptides of adenovirus type 16 incomplete particles. J. Virol. 22, 389-401.
42. YANG, X., AGARWALA, S., RAVINDRAN, S., and VELLEKAMP, G. (2003). Determination of particle heterogeneity of recombinant adenovirus by analytical ultracentrifugation in CsCl gradients. Mol. Ther. 7, S205-S206.
43. ZHANG, W., and IMPERIALE, M.J. (2003). Requirement of the ADENOVIRUS IVa2 protein for virus assembly. J. Virol. 77, 3586-3594.